Intralesional injection of the methanol extraction residue of bacillus calmette-guerin (MER) into cutaneous metastases of malignant melanoma

Krown, Susan E.; Hilal, Elias Y.; Pinsky, Carl M.; Hirshaut, Yashar; Wanebo, Harold J.; Hansen, John A.; Huvos, Andrew G.; Oettgen, Herbert F.

doi:10.1002/1097-0142(197812)42:6<2648::aid-cncr2820420621>3.0.co;2-j

Cited by 37 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Talimogene Laherparepvec (T-vec)mentioning

confidence: 99%

“…Intralesional bacillus Calmette-Guérin (BCG) has been shown to provide at least transient complete or partial responses in most injected lesions, with much higher response rates in cutaneous versus subcutaneous metastases (Table 3). [110][111][112] Although initial response rates are high for injected lesions, intralesional BCG is associated with a number of significant local and occasional systemic adverse effects.111-113 BCG injection has been largely supplanted by other local injection options and is rarely used in clinical practice.Rose bengal, a photosensitizing dye, is an investigational agent in development as another method for chemoablation of melanoma metastases by intralesional injection (using PV-10, a 10% w/v rose bengal saline solution). 114,115 It has similar activity to other intralesional agents, but is not currently available outside of the clinical trial setting (Clinicaltrials.gov indentifier: NCT02288897).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Coit¹,

Thompson²,

Algazi³

et al. 2016

J Natl Compr Canc Netw

219

167

View full text Add to dashboard Cite

OverviewIn 2016, an estimated 76,380 patients will be diagnosed with and approximately 10,130 patients will die of melanoma in the United States.1 However, these figures for new cases may represent a substantial underestimate, as many superficial and in situ melanomas treated in the outpatient setting are not reported. The incidence of melanoma continues to increase dramatically, at an overall rate of 33% for men and 23% women from 2002 to 2006.2 Melanoma is increasing in men more rapidly than any other malignancy, and in women more rapidly than any other malignancy except lung cancer. AbstractThis selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and highdose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted reassessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections. J Natl Compr Canc Netw 2016;14(4):450-473 NCCN Categories of Evidence and ConsensusCategory 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.All recommendations are category 2A unless otherwise noted.Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. Please NoteThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines ® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network ® (NCCN ® ) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way. The full NCCN Guidelines for Melanoma are not printed in this issue of JNCCN but can be accessed online at NCCN.org.© National Comprehensive Cancer Network, Inc. 2016, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. Disclosures for the NCCN Melanoma ...

show abstract

Section: Talimogene Laherparepvec (T-vec)mentioning

confidence: 99%

mentioning

confidence: 99%

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Coit¹,

Thompson²,

Algazi³

et al. 2016

J Natl Compr Canc Netw

219

167

View full text Add to dashboard Cite

show abstract

“…Later, accumulating pre-clinical evidence supported the use of BCG for cancer therapy (16). Clinicians reported the therapeutic benefits of intra-tumoral injections of BCG in several types of cancers such as melanoma (17–20) or squamous cell carcinoma of the head and neck (21). MD Anderson hospital reported up to 2500 patients with all types of cancer treated with BCG, including scarification of the tumors (22).…”

Section: Introductionmentioning

confidence: 99%

Intratumoral Immunization: A New Paradigm for Cancer Therapy

Marabelle

Kohrt

Caux

et al. 2014

Clinical Cancer Research

191

143

View full text Add to dashboard Cite

Immune cell infiltration in the tumor microenvironment is of prognostic and therapeutic import. These immune cell subsets can be heterogeneous and are composed of mature antigen presenting cells, helper and effector cytotoxic T cells, toleragenic dendritic cells, tumor associated macrophages, and regulatory T-cells, among other cell types. With the development of novel drugs that target the immune system rather than the cancer cells, the tumor-immune microenvironment is not only prognostic for overall patient outcome, but also predictive for likelihood of response to these immune-targeted therapies. Such therapies aim to reverse the cancer immunotolerance and trigger an effective anti-tumor immune response. Two major families of immunostimulatory drugs are currently in clinical development: pattern recognition receptor agonists (PRRagos) and immunostimulatory monoclonal antibodies (ISmAbs). Despite their immune targeted design, these agents have so far been developed clinically as if they were typical anti-cancer drugs. Here, we review the limitations of this conventional approach, specifically addressing the shortcomings of the usual schedules of intravenous infusions every two or three weeks. If the new modalities of immunotherapy target specific immune cells within the tumor microenvironment it might be preferable to deliver them locally into the tumor rather than systemically. There is pre-clinical and clinical evidence that a therapeutic systemic anti-tumor immune response can be generated upon intra-tumoral immunomodulation. Moreover, pre-clinical results have shown that therapeutic synergy can be obtained by combining PRRagos and ISmAbs to the local tumor site.

show abstract

“…Now, BCG after transurethral resection of the bladder tumor has been considered as standard therapy for high‐risk non–muscle‐invasive bladder tumor (DeGeorge, Holt, & Hodges, 2017). Besides, intratumoral administration of BCG has been tried to treat several types of cancer, such as oral tumor (Zbar, Canti, Rapp, Bier, & Borsos, 1979), lung cancer (Matthay et al, 1986), and melanoma (Krown et al, 1978; Silverstein, DeKernion, & Morton, 1974). At present, it is widely acknowledged that bacteria and its products could reverse tumor tolerance and boost the antitumor immune response by targeting intratumoral pattern recognition receptors (PRRs; Goutagny, Estornes, Hasan, Lebecque, & Caux, 2012; Paulos et al, 2007), and a rising number of bacteria were studied to cancer treatments.…”

Section: In Situ Antitumor Vaccination With Bacteria and Its Productsmentioning

confidence: 99%

In situ antitumor vaccination: Targeting the tumor microenvironment

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Tumor microenvironment is known to play important roles in tumor progression. Many therapies, targeting the tumor microenvironment, are designed and applied in the clinic. One of these approaches is in situ antitumor therapy. This way, bacteria, antibodies, plasmid DNA, viruses, and cells are intratumorally delivered into the tumor site as “in‐situ antitumor vaccine,” which seeks to enhance immunogenicity and generate systemic T cell responses. In addition, this intratumoral therapy can alter the tumor microenvironment from immunosuppressive to immunostimulatory while limiting the risk of systemic exposure and associated toxicity. Contemporarily, promising preclinical results and some initial success in clinical trials have been obtained after intratumoral therapy.

show abstract

Intralesional injection of the methanol extraction residue of bacillus calmette-guerin (MER) into cutaneous metastases of malignant melanoma

Cited by 37 publications

References 24 publications

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Intratumoral Immunization: A New Paradigm for Cancer Therapy

In situ antitumor vaccination: Targeting the tumor microenvironment

Contact Info

Product

Resources

About